Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
qpx9003
- Development stage
- Phase 1
- Lead developer
- Qpex Biopharma
- Modality
- Small Molecules, Modified Peptides → Peptides, Antimicrobial Peptides → Native Peptides → Peptides
- Administration
- Intravenous
01
Overview
QPX9003 is a next-generation, intravenously administered synthetic lipopeptide and polymyxin antibiotic designed to treat highly drug-resistant gram-negative bacterial infections, particularly those caused by *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. It was discovered at Monash University (Monash Institute of Pharmaceutical Sciences and Monash Biomedicine Discovery Institute) and developed in collaboration with Qpex Biopharma. The drug acts as a cell membrane structure inhibitor, disrupting the integrity of bacterial membranes to exert its antibacterial effect. Compared to existing polymyxins (such as colistin and polymyxin B), QPX9003 demonstrates enhanced potency against multidrug-resistant pathogens with reduced nephrotoxicity in preclinical studies. It has shown promising safety and tolerability in Phase 1 clinical trials, supporting further development for serious hospital-acquired infections including nosocomial pneumonia and ventilator-associated pneumonia[1][2][4][5][6].
- Brand names
- soralimixin
- Other names
- novel IV polymyxin antibiotic
Beyond the preview
Go deeper on qpx9003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on qpx9003.